To evaluate the efficacy and safety of Erlotinib and Bevacizumab in patients with advanced Non-squamous Non-Small Cell Lung Cancer with brain metastasis who acquired resistance to prior EGFR-TKI treatment harboring EGFR mutation.
Latest Information Update: 12 May 2016
At a glance
- Drugs Bevacizumab (Primary) ; Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 16 Dec 2013 New trial record